原癌基因ras的p21表达在癌前病变和高级别膀胱癌中增加。
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.
作者信息
Viola M V, Fromowitz F, Oravez S, Deb S, Schlom J
出版信息
J Exp Med. 1985 May 1;161(5):1213-8. doi: 10.1084/jem.161.5.1213.
Abstract
ras Oncogene p21 antigen is present in the most superficial cells of the normal bladder urothelium, as demonstrated by immunohistochemical staining. The pattern and intensity of p21 staining of cells in epithelial hyperplasia and low grade bladder carcinoma were similar to that seen in the normal urothelium. In contrast, epithelial cells in "premalignant" (dysplastic) lesions and high grade carcinomas exhibited an intense staining reaction for p21 antigen. ras p21 may be a useful marker for the malignant potential of both premalignant lesions and carcinomas of the bladder.
摘要
免疫组化染色显示，ras癌基因p21抗原存在于正常膀胱尿路上皮最表层的细胞中。上皮增生和低级别膀胱癌中细胞的p21染色模式和强度与正常尿路上皮中的相似。相比之下，“癌前”（发育异常）病变和高级别癌中的上皮细胞对p21抗原呈现强烈的染色反应。ras p21可能是膀胱癌前病变和癌恶性潜能的有用标志物。
相似文献
1
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.
J Exp Med. 1985 May 1;161(5):1213-8. doi: 10.1084/jem.161.5.1213.
2
Immunohistochemical study of the ras oncogene expression in human bladder endoscopy specimens.
Eur J Surg Oncol. 1990 Apr;16(2):153-60.
3
Expression of ras p21 oncogene product on human bladder tumors.
Urol Int. 1989;44(5):260-3. doi: 10.1159/000281520.
4
Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum.
Br J Cancer. 1985 Nov;52(5):695-700. doi: 10.1038/bjc.1985.245.
5
[Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Sep;41(9):1409-16.
6
Expression of ras oncogene p21 in prostate cancer.
N Engl J Med. 1986 Jan 16;314(3):133-7. doi: 10.1056/NEJM198601163140301.
7
p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.
Virchows Arch. 1994;424(4):349-55. doi: 10.1007/BF00190555.
8
Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium.
J Pathol. 1988 Sep;156(1):59-65. doi: 10.1002/path.1711560112.
9
Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas.
Cancer. 1989 May 15;63(10):2008-13. doi: 10.1002/1097-0142(19890515)63:10<2008::aid-cncr2820631024>3.0.co;2-d.
10
Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
J Clin Pathol. 2008 Mar;61(3):272-7. doi: 10.1136/jcp.2007.049684. Epub 2007 Aug 10.
引用本文的文献
1
In silico learning of tumor evolution through mutational time series.
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9501-9510. doi: 10.1073/pnas.1901695116. Epub 2019 Apr 23.
2
Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.
Int J Mol Med. 2017 Apr;39(4):861-868. doi: 10.3892/ijmm.2017.2903. Epub 2017 Feb 21.
3
Incorporating VEGF-targeted therapy in advanced urothelial cancer.
Ther Adv Med Oncol. 2017 Jan;9(1):33-45. doi: 10.1177/1758834016667179. Epub 2016 Sep 16.
4
P21 and CEA expression and AgNOR counts in dimethylhydrazine-induced colon carcinoma in rats.
World J Gastroenterol. 1997 Sep 15;3(3):163-5. doi: 10.3748/wjg.v3.i3.163.
5
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.
Oncotarget. 2015 Dec 15;6(40):42590-602. doi: 10.18632/oncotarget.6052.
6
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
Invest New Drugs. 2011 Oct;29(5):1045-9. doi: 10.1007/s10637-010-9408-4. Epub 2010 Feb 27.
7
Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.
World J Urol. 1996;14(3):190-6. doi: 10.1007/BF00186899.
8
Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats.
J Cancer Res Clin Oncol. 1993;119(8):482-5. doi: 10.1007/BF01215929.
9
Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.
Br J Cancer. 1994 Jun;69(6):995-9. doi: 10.1038/bjc.1994.195.
10
Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.
Urol Res. 1993 Jan;21(1):39-43. doi: 10.1007/BF00295190.
本文引用的文献
1
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.
Nature. 1982 Dec 23;300(5894):762-5. doi: 10.1038/300762a0.
2
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.
Nature. 1982 Nov 11;300(5888):149-52. doi: 10.1038/300149a0.
3
Classification of premalignant urothelial abnormalities. A Delphi study of the National Bladder Cancer Collaborative Group A.
Pathol Annu. 1982;17 (Pt 1):219-33.
4
Biological diversity in metastatic neoplasms: origins and implications.
Science. 1982 Sep 10;217(4564):998-1003. doi: 10.1126/science.7112116.
5
The relationship between non-invasive papillary lesions and invasive bladder carcinoma.
Cancer. 1984 Aug 15;54(4):620-3. doi: 10.1002/1097-0142(1984)54:4<620::aid-cncr2820540405>3.0.co;2-a.
6
Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation.
Cell. 1984 Feb;36(2):241-7. doi: 10.1016/0092-8674(84)90217-4.
7
Expression of cellular oncogenes in human malignancies.
Science. 1984 Apr 20;224(4646):256-62. doi: 10.1126/science.6538699.
8
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases.
Nature. 1984;311(5986):562-5. doi: 10.1038/311562a0.
9
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.
Proc Natl Acad Sci U S A. 1984 Aug;81(16):5227-31. doi: 10.1073/pnas.81.16.5227.
10
Cellular oncogenes and multistep carcinogenesis.
Science. 1983 Nov 18;222(4625):771-8. doi: 10.1126/science.6356358.
Zotero 插件